OUTLOOK THERAPEUTICS INC (OTLK)

US69012T3059 - Common Stock

7.78  +0.45 (+6.14%)

After market: 7.82 +0.04 (+0.51%)

News Image
3 days ago - BusinessInsider

OTLK Stock Earnings: Outlook Therapeutics Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Outlook Therapeutics (NASDAQ:OTLK) just reported results for the second quarter...

News Image
3 days ago - InvestorPlace

OTLK Stock Earnings: Outlook Therapeutics Misses EPS for Q2 2024

OTLK stock results show that Outlook Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

News Image
3 days ago - Outlook Therapeutics, Inc.

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

Positive opinion received from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for ONS-5010/LYTENAVA™...

News Image
6 days ago - Outlook Therapeutics, Inc.

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

UK submission for national MAA review follows recently received positive opinion from Committee for Medicinal Products for Human Use (CHMP) of the European...

News Image
10 days ago - Outlook Therapeutics, Inc.

Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first...

News Image
16 days ago - Outlook Therapeutics, Inc.

Outlook Therapeutics® to Present at the Retina World Congress 2024

ISELIN, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first...

News Image
19 days ago - Outlook Therapeutics, Inc.

Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

ISELIN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first...

News Image
a month ago - Outlook Therapeutics, Inc.

Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million

ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first...

News Image
a month ago - InvestorPlace

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential

With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks.

News Image
2 months ago - Outlook Therapeutics, Inc.

Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Positive opinion serves as a basis for final decision for potential authorization from the European Commission (EC), expected within 67 days ISELIN, N.J.,...

News Image
2 months ago - Outlook Therapeutics, Inc.

Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million

ISELIN, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed its previously announced private placement, for upfront gross proceeds of approximately $60 million from the issuance and sale of shares of the Company’s common stock and accompanying warrants, before deducting placement agent fees and offering expenses. Outlook Therapeutics has the potential to receive additional gross proceeds of up to $99 million upon the full cash exercise of the warrants issued in the private placement, before deducting placement agent fees and offering expenses.

News Image
2 months ago - Outlook Therapeutics, Inc.

Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split

ISELIN, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a biopharmaceutical company working to...

News Image
2 months ago - InvestorPlace

7 of the Best Speculative Stocks You Can Snag for Less Than $1

Although speculative stocks under $1 are by their very nature extremely risky, these ideas might have enough to go the distance.

News Image
3 months ago - InvestorPlace

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money.

News Image
3 months ago - Seeking Alpha

Outlook Therapeutics stock climbs 13% amid Chardan upgrade (NASDAQ:OTLK)

Shares of Outlook Therapeutics (OTLK) climbed 13% after Chardan upgraded the stock to buy, citing the company’s recent private placement and the full cash exerc

News Image
3 months ago - Outlook Therapeutics, Inc.

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update

NORSE EIGHT underway with first subject dosed and additional clinical sites beginning enrollment Continue to expect planned resubmission of the ONS-5010...

News Image
4 months ago - Outlook Therapeutics, Inc.

Outlook Therapeutics® Doses First Subject in NORSE EIGHT

NORSE EIGHT clinical trial is being conducted under Special Protocol Assessment (SPA) from FDA to support expected resubmission of the ONS-5010 Biologics...

News Image
4 months ago - Seeking Alpha

Outlook stock rallies on private placement, FDA study agreement (NASDAQ:OTLK)

Outlook Therapeutics (OTLK) stock rallied after it announced plans to privately place up to $172M of its securities and issued an update on key study for its eye drug ONS-5010.

News Image
5 months ago - THE ROSEN LAW FIRM, P. A.

OTLK FINAL DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLK

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between...

News Image
5 months ago - Levi & Korsinsky, LLP

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc.(OTLK) Investors of a Class Action Lawsuit and Upcoming Deadline

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ: OTLK) of a class action securities...

News Image
5 months ago - NewMediaWire

OTLK DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

News Image
5 months ago - NewMediaWire

OTLK IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

News Image
5 months ago - NewMediaWire

OTLK DEADLINE ALERT: ROSEN, A LEADING AND RANKED FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

News Image
5 months ago - NewMediaWire

OTLK DEADLINE ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

News Image
5 months ago - Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OTLK

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ:...